Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) have received an average recommendation of “Hold” from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $125.05.
Several research firms have recently weighed in on ZBH. Citigroup decreased their price target on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. UBS Group decreased their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, September 17th. Oppenheimer cut their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th.
Institutional Trading of Zimmer Biomet
Zimmer Biomet Trading Down 1.4 %
ZBH stock opened at $104.19 on Friday. The business’s 50-day moving average is $109.33 and its 200 day moving average is $114.30. Zimmer Biomet has a 12-month low of $102.00 and a 12-month high of $133.90. The stock has a market cap of $21.22 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.94 and a beta of 1.02. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.82 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet will post 8 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is currently 20.78%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured Articles
- Five stocks we like better than Zimmer Biomet
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- When Is the Best Time to Invest in Mutual Funds?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Is NVIDIA Stock in a Correction or Consolidation?
- What is the Euro STOXX 50 Index?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.